Activist investor Starboard Value takes $1 bln stake in Pfizer, sources say
Rewrites to change sourcing, adds details on stock price, M&A
Oct 6 (Reuters) -Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer PFE.N and wants the U.S. drug giant to make changes to turn its performance around, sources familiar with the matter said on Sunday.
Starboard has also approached Ian Read, a former Pfizer CEO, and Frank D'Amelio, who served as CFO until 2021, and both have expressed interest in helping the activist investor, the sources said.
Read served as CEO until Albert Bourla took the position in 2019. Bourla was instrumental in working with BioNTech to develop a COVID-19 vaccine.
Pfizer declined to comment and Starboard did not immediately respond to a Reuters request for comment.
Investors have punished the company as it navigates sharply lower sales for its COVID vaccines and drugs, a weaker-than-hoped launch of its respiratory syncytial virus (RSV) vaccine and disappointing clinical data for an obesity pill it was developing.
The company's stock price has fallen to $28.58 on Friday from approximately $41.00 in 2019 when Bourla took over.
While the company was quick in developing the vaccine during the pandemic, its fortunes have faded since the world normalized.
Bourla has also invested significantly on acquisitions, spending some $70 billion since 2020. It bought Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics (GBT) for $5 billion and Trillium for $2 billion.
Some investors have criticized the spree and expressed particular concern about GBT where its main sickle cell disease drug had to be pulled off the market and studies were discontinued because of adverse side effects.
The Wall Street Journal first reported news of Starboard's stake.
The investment firm has previously pushed for changes at News Corp NWSA.O, Salesforce CRM.N and Match Group MTCH.O.
Reporting by Svea Herbst-Bayliss in New York and Surbhi Misra in Bengaluru; Editing by Tom Hogue and Jacqueline Wong
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
